www.camurus.com Open in urlscan Pro
108.141.162.121  Public Scan

Form analysis
1 forms found in the DOM

/search/

<form class="_placeholder" action="/search/">
  <input type="text" placeholder="Search" aria-label="" class="_searchfield" name="q" value="" autocomplete="off">
  <button class="_searchsubmit">Search</button>
  <div class="_instantsearch" data-nohits="No results found"></div>
</form>

Text Content

Skip to main contentSkip to navigationSkip to search
   

 * About us
   * About us
   
   * Contact us
   
   * Our commitment
   * Business model
   * Board of directors
   * Management team
     * Alberto M. Pedroncelli
   * Code of conduct
 * Science
   * Science
   
   * 
   
   * Products
   * R&D pipeline
   * Technology
 * Disease areas
   * Disease areas
   
   * Read Will's story
   
   * Opioid dependence
   * Acromegaly
   * Neuroendocrine tumors
   * Polycystic liver disease
 * Sustainability
   * Sustainability
   
   * 
   
   * Governing documents
   * Patients
   * People
   * Planet
     * Transitionplan
   * Responsible business
 * Investors
   * Investors
   
   * 
   
   * The share
   * Press releases
   * Events and presentations
     * Capital Markets Day
   * Financial calendar
   * Financial reports
   * Corporate governance
     * Committees
     * Remuneration
     * General meetings
     * Auditors
     * Incentive programs
     * Articles of association
     * Nomination Committee
     * AGM
   * General meetings
   * CEO message
   * Investor contact
   * Subscription
 * Partnering
 * Media
   * Media
   
   * 
   
   * Press releases
   * Media contact
   * Media archive
 * Career
 * Contact

Search

English
EnglishSvenska


DELIVERING BETTER TREATMENTS

Camurus is committed to improving the lives of patients
with severe and chronic diseases

Read more


UPDATES


LATEST NEWS

All press releases

28 June 2024


CHANGE IN NUMBER OF SHARES AND VOTES IN CAMURUS

Press release Regulatory
25 June 2024


NEW PUBLICATION SHOWS EFFECTIVENESS DATA FOR WEEKLY AND MONTHLY BUPRENORPHINE
INJECTIONS IN TREATING OPIOID DEPENDENCE IN INDIVIDUALS USING FENTANYL

Press release
24 June 2024


CAMURUS SUBMITS ITS FIRST UN GLOBAL COMPACT COMMUNICATION ON PROGRESS AND RENEWS
THE NASDAQ TRANSPARENCY PARTNER CERTIFICATE

News

All press releases

Disease areas


FOCUS ON SEVERE AND CHRONIC DISEASES

Developing treatments for diseases within the central nervous system, rare
diseases, endocrinology, oncology and supportive care

Learn more on disease areas

Events


UPCOMING EVENTS


See all events

 * 16 Jul
   
   
   INTERIM REPORT JANUARY-JUNE 2024
   
   The interim report January-June is published on 16 July 2024.
   
   Add to calendar

 * 16 Jul
   
   
   INTERIM REPORT JANUARY-JUNE 2024 – AUDIOCAST
   
   Financial analysts and media are invited to attend a telephone conference and
   presentation of the second quarter results at 2.00 pm CET. Audiocast
   
   Add to calendar

 * 21 Aug
   
   
   SEB NORDIC LARGE CAP SEMINAR
   
   Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in
   Stockholm, 21 August, at 12.50 CEST. The presentation can be seen by the
   conference participants. 
   
   Add to calendar





Latest financial report


CAMURUS’ INTERIM REPORT JANUARY-MARCH 2024

8 May 2024

 * Report Camurus’ Interim Report January-March 2024
 * Presentation Camurus’ Interim Report January-March 2024
 * Audiocast Camurus’ Interim Report January-March 2024

Go to report archive



Products




ADDRESSING IMPORTANT UNMET MEDICAL NEEDS

Learn about our products

Stories




LIVING WITH OPIOID DEPENDENCE

Read Daniel's story


ANNUAL REPORT 2023

Camurus Annual Report 2023 (pdf)

Camurus Annual Report 2023 (ESEF/ZIP) (In Swedish)


ANNUAL GENERAL MEETING

Camurus’ Annual General Meeting 2024 was held on Wednesday, 8 May 2024 at Elite
Hotel Ideon in Lund, Sweden.

See documents for Annual General Meeting 2024
See resolutions at the Annual General Meeting 2024
See more information on Camurus' general meetings

Pipeline


DIVERSIFIED PIPELINE WITH LARGE POTENTIAL

Camurus' innovative product candidates are designed to address important unmet
medical needs, with the potential to make significant difference in the daily
life of patients by improving treatment outcomes, quality of life, and long-term
recovery.

See pipeline

sustainability


SUSTAINABLE SOLUTIONS FOR A HEALTHIER WORLD

Ensuring the long-term successful development of our business – for the benefit
of patients, healthcare systems, employees and shareholders.

Learn more






QUICKLINKS

 * Contact
 * About us
 * Pipeline
 * Products


INVESTORS

 * Press releases
 * Financial reports
 * IR contact


ADDRESS

Camurus AB
Ideon Science Park
SE-223 70 Lund, Sweden




 * Terms of Use
 * Privacy notice
 * Cookie policy

Camurus AB - all rights reserved
English
EnglishSvenska

This website uses cookies to provide the best possible user experience. By
accepting you consent to cookies being used. If you want to find out more or
disable cookies, please click here.

Reject Accept all